Posted by Michael Wonder on 13 Dec 2024
Allay Therapeutics receives FDA breakthrough therapy designation for ATX101 for the treatment of post-surgical pain following total knee replacement surgery
4 December 2024 - Breakthrough therapy designation supported by results from a Phase 2 dose-ranging trial.
Allay Therapeutics today announced that the US FDA has granted breakthrough therapy designation for its lead investigational product ATX101 for treatment of post-surgical pain following total knee arthroplasty procedures in adults.
